Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for myelofibrosis patients: experimental drug RVU120 enters Mid-Stage trial

NCT ID NCT06397313

Recruiting now Disease control Sponsor: Ryvu Therapeutics SA Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This Phase 2 trial tests a new drug called RVU120, alone or with the standard drug ruxolitinib, in 230 adults with intermediate or high-risk myelofibrosis. The main goal is to see if the drug can shrink the spleen and improve symptoms. Participants must have not responded well to prior JAK inhibitor treatment or be unable to take it.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
RVU120 (a CDK8/CDK19 inhibitor) and ruxolitinib (a JAK inhibitor)
What this could lead to
If successful, this could offer a new treatment option for people with myelofibrosis who have not responded well to current therapies.
What could go wrong
This is an early Phase 2 trial, so the drug may not work as hoped or could cause unexpected side effects. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelofibrosis Neoplasm Metastasis primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOFIBROSIS

Contacts and locations

Locations

  • Azienda Ospedaliero Universitaria Policlinico "G. Rodolico - San Marco"

    RECRUITING

    Catania, Italy

  • Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia

    RECRUITING

    Brescia, Italy

  • Centrum Wsparcia Badań Klinicznych UCK Ośrodek Badań Klinicznych Wczesnych Faz

    RECRUITING

    Gdansk, Poland

  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico

    RECRUITING

    Milan, Italy

  • Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l.

    RECRUITING

    Meldola, Italy

  • Lux Med Onkologia Sp. z o.o.

    RECRUITING

    Warsaw, Poland

  • M2M Med. Sp. z o.o. Sp. j.

    RECRUITING

    Chorzów, Poland

  • Policlinico Sant'Orsola-Malpighi

    RECRUITING

    Bologna, Italy

  • Pratia Hematologia Sp. z o.o.

    RECRUITING

    Katowice, Poland

  • Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie

    RECRUITING

    Lublin, Poland

  • Samodzielny Publiczny Zakład Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie

    RECRUITING

    Krakow, Poland

  • Szpital Uniwersytecki Imienia Karola Marcinkowskiego w Zielonej Gorze Sp. z o. o.

    COMPLETED

    Zielona Góra, Poland

  • Szpital Uniwersytecki nr 2 im. dr Jana Biziela

    RECRUITING

    Bydgoszcz, Poland

  • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu

    RECRUITING

    Wroclaw, Poland

  • Wojewódzki Szpital Specjalistyczny w Białej Podlaskiej

    RECRUITING

    Biała Podlaska, Poland

  • Wojewódzki Szpital Zespolony im. L. Rydygiera w Toruniu

    RECRUITING

    Torun, Poland

  • Wojskowy Instytut Medyczny Państwowy Instytut Badawczy

    RECRUITING

    Warsaw, Poland

  • Świętokrzyskie Centrum Onkologii Samodzielny Publiczny Zakład Opieki Zdrowotnej

    COMPLETED

    Kielce, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.